<DOC>
	<DOC>NCT02370680</DOC>
	<brief_summary>This study is being conducted to evaluate the safety and the length of effect on platelet build-up in the arteries of Durlaza™ as compared to immediate-release Bayer® aspirin 81 mg or subject's current aspirin 81 mg of choice in patients who have Type 2 diabetes mellitus and cardiovascular disease or multiple risk factors of developing cardiovascular disease.</brief_summary>
	<brief_title>Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Male or nonlactating, nonpregnant female subjects A history of Type 2 Diabetes and with history of at least one of the following: Coronary Artery Disease, Peripheral Vascular Disease, or Ischemic Stroke, along with at least 2 CVD risk factors (obese, smoker, ≥ 55 years of age, prior thrombotic event) Sensitivity to aspirin or any NSAID (nonsteroidal antiinflammatory drug), Evidence of uncontrolled or unstable cardio or cerebrovascular disorder, Presence of uncontrolled or chronic medical illness, GI disorder or surgery leading to impaired drug absorption, clinically significant abnormal baseline ECG, history of hepatitis, malignancy within the past five years, or HIV, history of alcohol or drug abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Antiplatelet</keyword>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>platelet turnover</keyword>
	<keyword>high platelet turnover</keyword>
	<keyword>platelet aggregation</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>diabetes mellitus</keyword>
</DOC>